[HTML][HTML] Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
SJ Schuster, MR Bishop, CS Tam… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor …
second-line therapies or that has relapsed after stem-cell transplantation have a poor …
[HTML][HTML] Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B …
Introduction Axi-cel is approved in the US for the treatment of adult patients with relapsed or
refractory large B cell lymphoma after 2 or more lines of systemic therapy. A post-marketing …
refractory large B cell lymphoma after 2 or more lines of systemic therapy. A post-marketing …
[HTML][HTML] A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …
impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma …
[HTML][HTML] Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell …
Background: Tisagenlecleucel, an anti-CD19 chimeric antigen receptor (CAR)-T cell
therapy, has demonstrated durable responses and a manageable safety profile in adult …
therapy, has demonstrated durable responses and a manageable safety profile in adult …
[HTML][HTML] End of phase 1 results from Zuma-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse …
Background: Axi-cel is a US FDA-approved autologous anti-CD19 chimeric antigen receptor
(CAR) T cell therapy for treatment of adult patients (pts) with relapsed or refractory large B …
(CAR) T cell therapy for treatment of adult patients (pts) with relapsed or refractory large B …
[HTML][HTML] Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma
Abstract BACKGROUND: CTL019 (tisagenlecleucel) is an investigational chimeric antigen
receptor (CAR) T-cell therapy that identifies and eliminates CD19-expressing B cells …
receptor (CAR) T-cell therapy that identifies and eliminates CD19-expressing B cells …
[HTML][HTML] Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
M Kwon, G Iacoboni, JL Reguera, LL Corral… - …, 2023 - ncbi.nlm.nih.gov
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric
antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma …
antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma …
[HTML][HTML] Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: an updated analysis of Juliet, a global pivotal phase 2 …
SJ Schuster, MR Bishop, C Tam, P Borchmann… - Blood, 2018 - Elsevier
Abstract BACKGROUND JULIET (NCT02445248) is a single-arm, open-label, multicenter,
global, pivotal phase 2 trial of tisagenlecleucel, a chimeric antigen receptor (CAR)-T cell …
global, pivotal phase 2 trial of tisagenlecleucel, a chimeric antigen receptor (CAR)-T cell …
[HTML][HTML] Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell …
Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy
approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated …
approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated …
Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene
ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for …
ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for …